[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100540698":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":36,"collaborators":10,"id":38,"slug":10,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":11,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":10,"enrollmentInfo":46,"targetDuration":49,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"University Hospital, Essen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Prostate cancer patients with PSMA PET",null,"Inclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer.",[13],{"name":14,"affiliation":5,"role":15},"Wolfgang P Fendler, M.D.","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+492017232032","redcap@ikim.nrw",[22],{"facility":23,"status":24,"city":25,"state":10,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"University Hospital Essen","RECRUITING","Essen","45147","Germany",{"type":29,"coordinates":30},"Point",[31,32],7.01228,51.45657,{"lat":32,"lon":31},[35],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100540698",false,"NCT06320223","PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer","PROMISE Registry on Standardized Evaluation of PSMA-PET and Outcome in Prostate Cancer","PROMISE-PET","MALE","18 Years",{"count":47,"type":48},10000,"ESTIMATED","10 Years","OBSERVATIONAL","Background:\n\nPROMISE criteria have been defined for standardized reporting of Prostate-Specific Membrane Antigen (PSMA) PET whole-body stage of prostate cancer. PSMA PET disease extent by PROMISE has been associated with oncologic outcome.\n\nNeed:\n\nImproved prognostication across various stages of prostate cancer is needed for management guidance and study design.\n\nAim:\n\n1. To assess the prognostic value of PSMA PET\n2. To compare the prognostic value of PSMA PET with clinical prognostic scores in patients with prostate cancer at various disease stages\n\nInclusion:\n\n* Adult patients with\n* biopsy\u002Fhisto proven prostate cancer who\n* underwent PSMA PET (any type)\n* for staging or re-staging at any stage and who\n* have at least 3-year overall survival follow-up data available will be included consecutively.\n\nExclusion:\n\n* Patients with neuroendocrine prostate cancer\n* Patients with metastasized or disseminated malignancy other than prostate cancer",[53,54,55,56],"Prostate Cancer","PET\u002FCT","Survivorship","PSMA",[53,54,55,56,58,59,60,61],"Nuclear Medicine","Imaging","Oncology","Urology","2024-03-15",{"date":64,"type":65},"2024-03-20","ACTUAL",{"date":67,"type":65},"2024-03-05",{"date":69,"type":48},"2035-03-05",{"name":5,"class":6},1]